Fig. 2: Th1/Th2 skew in response to SARS-CoV-2 saRNA LNP vaccine in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
"a) IgG1 and IgG2a responses in mice vaccinated with doses of LNP-formulated saRNA ranging from 0.01–10 μg of saRNA with n = 7 biologically independent animals
b) Th1/Th2 skewing responses in mice vaccinated with doses of LNP-formulated saRNA ranging from 0.01–10 μg of saRNA with n = 7 biologically independent animals, and 10 μg of electroporated pDNA (EP pDNA) with n = 8 biologically independent animals. The asterisk (*) indicates significance of p < 0.05 as determined by a Kruskal–Wallis test. Line and error bars indicated mean ± SD."
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Fig. 1: Antibody quantification and neutralization of a SARS-CoV-2 saRNA vaccinated mice compared to COVID-19 recovered patients in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Fig. 2: Th1/Th2 skew in response to SARS-CoV-2 saRNA LNP vaccine in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice